Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Mesoblast Limited ( (AU:MSB) ) is now available.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Mesoblast Limited, a company involved in the biopharmaceutical industry. This change in holding reflects a series of transactions involving the purchase, sale, and lending of securities, which resulted in a decrease in their voting power in the company.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Average Trading Volume: 6,028,786
Technical Sentiment Signal: Hold
Current Market Cap: A$2B
See more data about MSB stock on TipRanks’ Stock Analysis page.